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Abstract
Objective: To determine the association between HbA1c, fasting plasma glucose (FPG), 1-hour (1 hPG) and 2-hour (2 hPG)
glucose after an oral glucose tolerance test (OGTT) and cardiovascular disease in individuals with elevated risk for diabetes.
Design: We studied the relationship between baseline, updated mean and updated (last) value of HbA1c, FPG, 1 hPG and
2 hPG after an oral 75 g glucose tolerance test (OGTT) and acute CVD events in 504 individuals with impaired glucose
tolerance (IGT) at baseline enrolled in the Finnish Diabetes Prevention Study.
Setting: Follow-up of clinical trial.
Participants: 504 individuals with IGT were followed with yearly evaluations with OGTT, FPG and HbA1c.
Main Outcome Measure: Relative risk of CVD.
Results: Over a median follow-up of 9.0 years 34 (6.7%) participants had a CVD event, which increased to 52 (10.3%) over a
median follow-up of 13.0 years when including events that occurred among participants following a diagnosis of diabetes.
Updated mean HbA1c, 1 hPG and 2 hPG, HR per 1 unit SD of 1.57 (95% CI 1.16 to 2.11), p = 0.0032, 1.51 (1.03 to 2.23),
p = 0.036 and 1.60 (1.10 to 2.34), p = 0.014, respectively, but not FPG (p = 0.11), were related to CVD. In analyses of the last
value prior to the CVD event the same three glycaemic measurements were associated with the CVD events, with HRs per
1 unit SD of 1.45 (1.06 to 1.98), p = 0.020, 1.55 (1.04 to 2.29), p = 0.030 and 2.19 (1.51 to 3.18), p,0.0001, respectively but
only 2 hPG remained significant in pairwise comparisons. Including the follow-up period after diabetes onset updated
2 hPG (p = 0.003) but not updated mean HbA1c (p = 0.08) was related to CVD.
Conclusions and Relevance: Current 2 hPG level in people with IGT is associated with increased risk of CVD. This supports
its use in screening for prediabetes and monitoring glycaemic levels of people with prediabetes.
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Introduction
The global prevalence of diabetes is increasing rapidly, and in
2030 over 500 million individuals are expected to suffer from
diabetes, mostly type 2 (T2D) [1]. T2D is a progressive disease,
both in terms of glycaemia and its resulting complications. In
order to halt diabetes progression in high-risk individuals and to
avoid the likely burden of future diabetic complications, manage-
ment of individuals with prediabetes, characterized as having
above-normal blood glucose levels, but not meeting the diagnostic
criteria of diabetes needs to be focused upon [2]. The landmark
Finnish Diabetes Prevention Study (DPS) showed that intensive
lifestyle intervention among individuals with impaired glucose
tolerance (IGT) effectively prevented progression from IGT to
diabetes [3]. This benefit has been subsequently confirmed by
others [4,5].
The collaborative Diabetes in Europe: Classification and
Diagnostic Criteria (DECODE) study confirmed that asymptom-
atic hyperglycaemia is associated with an increased risk of
premature mortality and cardiovascular disease (CVD, [6]). In
particular, there was a graded relationship between mortality and
2-hour post-challenge plasma glucose (2 hPG). However, few
studies have examined the effects of intensive glycaemic manage-
ment in individuals with prediabetes in order to prevent CVD,
mortality or other complications due to hyperglycaemia, and
results have been equivocal [7,8]. In a recent systematic review,
the relationships between 2-h plasma glucose (2 hPG) and fasting
plasma glucose (FPG) and risk of future CVD and mortality were
shown to be relatively weak [2]. However, these studies only
examined baseline FPG and 2 hPG measurements, thereby
information on glycaemic control during follow-up (i.e., when
the events actually occurred), may have weakened the associations.
Moreover, it is unclear whether prediabetes per se and/or the
development of diabetes during a later point in time is relevant to
the association between IFG, IGT and CVD events, as well as
relevant confounders including physical activity, which were
generally missing in previous studies [2].
To address this gap in knowledge we studied data from the
original DPS trial, including FPG, 1 hPG, 2 hPG and HbA1c in
relation to the development of CVD [3], as well as extended
follow-up data that included regularly recorded glucose measure-
ments but not continued intensive lifestyle intervention.
Methods
Participants
The DPS design and study participants have been described in
detail elsewhere (NCT00518167, clinicaltrials.gov) [3]. In brief,
the DPS examined the extent to which lifestyle intervention can
prevent or delay the future onset of diabetes in individuals with
IGT. The original randomized phase of the trial ended in 2001,
and an extended follow-up phase was performed afterward. An
OGTT was completed on each annual visit with measurements of
FPG, 1 hPG, 2 hPG and HbA1c during both phases. Information
on medication use and CVD events were obtained by linking trial
data to the Finnish national drug prescription register, death
register and hospital discharge register.
Among the original cohort of 522 individuals, 17 did not
consent to record linkage, leaving 505 individuals available for the
current analysis. One individual was excluded due to lack of
information on the timing of diabetes diagnosis during follow-up.
The study protocol was approved by the Ethics Committee of
the National Public Health Institute in Helsinki, Finland and all
the study participants gave written informed consent.
Procedures
An incident CVD event was defined as a composite endpoint of
the first myocardial infarction, stroke, unstable angina, coronary
artery bypass graft or percutaneous coronary intervention (PCI).
ICD-8 and 9 codes 410, 4110, 431, 433, 4330A, 4331A, 4339A,
434, 4340A, 4341A, 4349A, 436 and ICD-10 codes I200, I21, I22,
I61, I63, I64 were used to obtain event data.
We analysed the relation between the composite CVD events
and baseline, updated values, and updated mean FPG, 1 hPG,
2 hPG and HbA1c measurements. The updated value was defined
as the most recent recording of a glucose measurement prior to an
event or the end of follow-up for an individual. The updated mean
is defined as the mean value at every recording of a new glucose
measurement and includes all follow-up recordings prior to the
event or end of follow-up [8]. Updated mean HbA1c has been
shown to have greater predictive power for diabetic complications
than the use of baseline variables alone in prospective studies in
patients with types 1 and 2 diabetes [9]. To be included in the
analyses, glucose measures had to exist at baseline or year 1.
Missing baseline values were extrapolated from year 1 data,
concerning 11 values of HbA1c and 61 values of 1 hPG. In
analyses of FPG and the 2 hPG value in relation to CVD, all 504
individuals had information at baseline and were included in the
analysis. The number of individuals with information at baseline
or at year 1 included in the 1 hPG and HbA1c analyses was 498
and 502, respectively. In main analyses, individuals were followed
until the first CVD event being considered as failure, or onset of
diabetes, death or end of follow-up, defined as the last time point
when all data and glucose measures were updated for each
participant, or December 2009, whichever of them occurred first
being considered as censoring event.
Statistics
FPG, 1 hPG, 2 hPG and HbA1c were separately analyzed in
relation to CVD incidence, adjusting for potential confounders.
Stepwise adjustment for potential confounders was performed,
initially for age, sex and smoking (Model 1), then adding body
mass index (BMI) and physical activity (Model 2), and further
adding systolic blood pressure (BP), low density (LDL) and high
density (HDL) lipoprotein cholesterol (Model 3). The final model
was additionally adjusted for history of CVD and cancer (Model
4). A sensitivity analysis was performed to determine whether
group allocation or insulin resistance, measured by fasting serum
insulin, contributed to risk of CVD. An additional sensitivity
analysis was performed to include time and CVD events after
diabetes onset by the 4 glycaemic measures, including the
additional follow-up period at diabetes onset. A subgroup analysis
investigating relation between FPG, 1 hPG, 2 hPG and HbA1c
and the CVD incidence has been performed on patients with
impaired fasting glucose (IFG), defined as FPG greater or equal to
5.6 mmol/l, at baseline (by definition, all of them had also IGT).
Semi-parametric Cox regression analysis was used to study the
relation of the four glycaemic measures to CVD incidence. This
method does not use any restriction on the baseline hazard
function. The proportional hazards assumption was tested by
including interaction terms for each covariate with the log(time)
and was fulfilled for all glycaemic measures [10]. Potential
confounders for the risk of CVD were included as baseline
variables in a step-wise procedure (described above). Hazard ratios
(HR) were estimated for each unit increase in the glycaemic
measures. For the updated means and updated values, the HR per
1 unit increase in standard deviation (SD) was also estimated,
assuming a normal distribution before estimating each HR.
Updated mean and updated values of glycaemic measures having
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significant associations with CVD incidence were also analyzed
pairwise in additive Cox models, as well as including all 4 main
glycaemic variables at the same time, adjusting for all potential
confounders.
Results
Characteristics of the cohort
Baseline characteristics are shown in Table 1. The mean age at
baseline was 55.2 years, 32?9% were men, mean BMI was
31.3 kg/m2, and 6.0% were active smokers. Mean baseline FPG
was 6.1 mmol/l, 1 hPG was 11.3 mmol/l, 2 hPG was 8.9 mmol/l
and HbA1c was 5.6% (37.7 mmol/mol).
The composite CVD endpoint occurred in 34 (6.7%) individ-
uals over a median follow-up period of 9.0 years, 8.0 events per
1000 patient-years, in participants during the prediabetic phase.
When the length of follow-up after diabetes onset was also
included, there were 52 (10.3%) composite endpoints over a
median follow-up of 13.0 years, 9.3 events per 1000 patient-years.
Figure 1 shows the mean level and number of measurements of
FPG, 1 hPG, 2 hPG and HbA1c for participants who did not
develop diabetes during the first 10 years of follow-up. Mean FPG
levels ranged between 6.0–6.3 mmol/l, 1 hPG from 10.3–11.2,
2 hPG from 8.1–8.7 and HbA1c from 5.5%–5.6% (36.6–
37.7 mmol/mol).
Updated mean and updated value of FPG, 1 hPG, 2 hPG
and HbA1c
Relative risks of CVD events for the four glycaemic measures
were estimated in stepwise increasing covariate models (Table 2).
Updated mean and updated value of FPG was not associated with
the incidence of CVD events in any of the four models (Table 2).
There was a significant direct association between 1 hPG as well
as 2 hPG and incidence of CVD events in all four models for both
updated mean and updated values of these measurements. There
was a direct and statistically significant relation between higher
updated mean/updated value of HbA1c and incidence of CVD
events.
When updated means of 1 hPG and 2 hPG were included
pairwise in the same Cox regression model adjusting for all
possible confounders, the HRs were 1.14 (0.90–1.44), p = 0.28 for
1 hPG and 1.29 (0.93–1.80), p = 0.12 for 2 hPG. The HR for
updated mean of 1 hPG was 1.13 (0.90–1.41), p = 0.29 and 2.19
(1.03–4.69), p = 0.043 for updated mean of HbA1c when included
pairwise in the model. The HRs for updated mean 2 hPG and
HbA1c were 1.30 (0.95–1.76), p = 0.10 and 2.22 (1.08–4.59),
p = 0.031, respectively, when included pairwise in the model.
When updated 1 hPG and 2 hPG values were included pairwise
in the same Cox regression model adjusting for all possible
confounders, the HRs were 1.00 (0.82–1.21), p = 0.99 for 1 hPG
and 1.45 (1.17–1.79), p = 0.0006 for 2 hPG. The HRs for updated
1 hPG and updated HbA1c were 1.14 (0.96–1.35), p = 0.13 and
1.65 (0.89–3.06), p = 0.11, respectively, and for 2 hPG and HbA1c
were 1.40 (1.17–1.68), p = 0.0002 and 1.49 (0.81–2.74), p = 0.20,
respectively, when included pairwise in the model.
When all four glycaemic variables were included as time-
updated values in the same model including all possible
confounders, the only glycaemic predictor that remained statisti-
cally significant was 2 hPG with HR of 1.44 (1.16–1.78),
p = 0.0009.
Baseline value of the four glucose measures
HRs for higher baseline values of the four glycaemic measures
were greater than one in all models, although in all four models
the association between each of the four measures and the
incidence of CVD was not statistically significant (Table 2).
Gradient of risk per 1- unit SD increase for updated mean
and updated value of 1 hPG, 2 hPG and HbA1c
Since the updated mean values and updated values of 1 hPG,
2 hPG and HbA1c were significantly related to CVD, we
standardised the risk gradients by estimating the HRs per 1 SD
increment for each glycaemic measure. HRs estimates for the
updated mean of 1 hPG, 2 hPG and HbA1c ranged from 1.45–
1.51, 1.59–1.73 and 1.43–1.57 per 1-unit increase in the SD,
respectively, in the four models (Table 3). For the updated values
of 1 hPG, 2 hPG and HbA1c the HRs ranged from 1.51–1.57,
2.17–2.28 and 1.36–1.45 per 1-unit increase in the SD,
respectively.
Sensitivity analysis
Neither the group allocation nor insulin resistance showed any
significant association to the risk of CVD.
There were 239 individuals in the entire cohort who developed
diabetes during the entire study period. In the sensitivity analysis
including time after diabetes onset, the HRs for the updated means
of FPG, 1 hPG, 2 hPG and HbA1c were 1.25 (0.85–1.83),
p = 0.26, 1.17 (1.03–1.34), p = 0.018, 1.16 (0.99–1.35), p = 0.061
and 1.57 (0.94–2.60), p = 0.082, respectively. For updated values
the corresponding HRs were 1.20 (0.94–1.53), p = 0.15, 1.12
(1.01–1.23), p = 0.027, 1.13 (1.04–1.23), p = 0.0031 and 1.43
(0.99–2.08), p = 0.059 for FPG, 1 hPG, 2 hPG and HbA1c,
respectively.
Subgroup analysis of patients with impaired fasting
glucose
A subgroup analysis was performed in patients with impaired
fasting glucose (76% of all patients). Unlike the results obtained in
the main analyses, updated mean and baseline FPG were
statistically significantly associated with the incidence of CVD
events in all 4 models, with HR (95% CI) 2.37 (1.0825.17),
p = 0.031, and 2.22 (1.0524.70), p = 0.038, respectively in model
4. In the analyses of last updated value the only significant
predictor was 2 hPG with HR from model 4 being 1.52 (1.212
1.91), p = 0.0004. Similarly, the sensitivity analyses on this
subgroup of patients showed only significant association between
updated last value of 2 hPG and the incidence of CVD, 1.13
(1.0321.24), p = 0.0093.
Discussion
These new data from the DPS are the first to evaluate the
association between glycaemic level and CVD incidence during a
prediabetes phase by censoring patients with later development of
diabetes based on annual repeated OGTTs. Thus this study is also
the first prospective study with systematically repeated assessment
of glycaemic values during the follow-up phase among prediabetic
individuals. An increased level of the current 2 hPG, recorded as
the updated (last) value of yearly estimates of 2 hPG during follow-
up, was related to increased risk of CVD independent of other
glycaemic markers such as FPG, 1 hPG and HbA1c in all models
used to control effects of other variables. The current level of
2 hPG at the last visit before the CVD event also showed the
highest risk increase for CVD (119%) when the various glucose
measures were standardised to 1 SD increment. The current level
of 2 hPG was also strongly associated with increased risk of CVD
in sensitivity analyses including the follow-up time after diabetes
diagnosis and in a subgroup analysis including patients with both
HbA1c, Fasting Glucose, 1 h and 2 h Glucose and Cardiovascular Disease
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IFG and IGT. Higher mean level of historical HbA1c-values was
also independently related to an increased risk of CVD during the
prediabetic phase, but this was not confirmed in sensitivity
analyses including follow-up time after diabetes onset. An
increased level of FPG was not associated with higher risk of
CVD in any models of the study population but an association was
found in the subgroup analysis of patients with IFG at baseline.
1 hPG was associated with increased risk of CVD in some models
Table 1. Baseline characteristics of the study cohort.
DPS CVD (n=504)
Age (years) at Baseline 55.2 (7.1)
57.0 (39.5; 67.9)
n = 504
Gender
Male 166 (32.9%)
Female 338 (67.1%)
Smoking at Baseline
Non-smoker 474 (94.0%)
Smoker 30 (6.0%)
BMI (kg/m2) at Baseline 31.3 (4.5)
30.4 (23.5; 50.5)
n = 504
Leisure-time physical activity at Baseline
None 174 (34.6%)
,= 4 h per Week 277 (55.1%)
.4 h per Week 52 (10.3%)
SBP (mmHg) at Baseline 138.1 (17.7)
135.0 (98.0; 200.0)
n = 504
HDL (mmol/L) at Baseline 1.21 (0.29)
1.18 (0.59; 2.56)
n = 503
LDL (mmol/L) at Baseline 3.61 (0.82)
3.60 (1.68; 6.30)
n = 501
Previous CVD Events
No 489 (97.0%)
Yes 15 (3.0%)
Previous Cancer
No 487 (96.6%)
Yes 17 (3.4%)
Fasting Plasma Glucose (mmol/l) at Baseline 6.14 (0.76)
6.11 (3.73; 8.78)
n = 504
One-hour Plasma Glucose (mmol/l) at Baseline 11.3 (2.3)
11.2 (4.5; 18.6)
n = 498
Two-hour Plasma Glucose (mmol/l) at Baseline 8.89 (1.49)
8.72 (4.70; 13.71)
n = 504
HbA1c (%) at Baseline 5.63 (0.57)
5.60 (3.60; 8.00)
n = 502
For categorical variables n (%) is presented.
For continuous variables Mean (SD)/Median (Min; Max)/n = is presented.
doi:10.1371/journal.pone.0109506.t001
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when included as the only glucose measure, but not independently
when combined with other glucose measures in the same model.
Since baseline values of glucose measures were generally poor
predictors of CVD for all glucose measures, it raises the question of
the validity of prospective studies where baseline data only have
been available.
There are several previous studies using a single baseline value
for glucose measures in predicting CVD or mortality but did not
have information on later time measures after onset of diabetes
[2]. This may be due to the fact that regular screening is needed to
determine the true time of onset for diabetes, thus requiring
greater resources. In such studies 2 hPG has generally been a
stronger predictor than FPG for CVD and mortality [2,6,11]. A
number of studies have also compared the predictive ability of
FPG, 2 hPG and HbA1c for CVD or mortality in the same study
population [12–16]. In the Rancho Bernardo Study [12], HbA1c
was found to be a better predictor of CVD and ischaemic heart
disease mortality than FPG or 2 hPG in women only. In contrast,
other studies found that post-load 2 hPG was a better predictor of
mortality and/or CVD outcomes than FPG or HbA1c [13–15]. In
a study by Barr and colleagues [16], 2 hPG and FPG, but not
HbA1c, were significant predictors of all-cause mortality, whereas
all measures were significant predictors of CVD mortality. In a
population-based prospective study among Finnish middle-aged
people with IGT at baseline, those who had started with
antidiabetic drug treatment during 10-year follow-up were
identified [17]. The HRs for CHD incidence and mortality did
not differ between those who had and had not developed diabetes
before the CVD event. Monnier and colleagues showed that when
HbA1c is below 7.3%, the contribution of postprandial, not
fasting, glucose level is predominant [18], which has however been
challenged in other studies [19]. The increased glucose level has
also been associated with the CVD mortality in the newly
diagnosed T2D patients [20].
The risk gradient in the current study of the updated value of
2 hPG was strong when compared with previous studies including
people with prediabetes [2,12,16]. It was also strong when
compared with relations observed between HbA1c and CVD
among T2D patients where 1 SD higher HbA1c has been
associated with a 25% increased risk of MI [9]. The current value
of 2 hPG showed the strongest association with CVD, with a
119% increased risk per 1-unit higher SD 2 hPG and 51%
increased risk if the lower boundary of the 95% CI is true. Such
strong associations to CVD during the prediabetes phase may be
due to our use of repeated measurements and updated recent
values of glycaemia instead of using only baseline values. The
general lack of relationships between baseline values of various
glucose measures and risk of CVD in the present analysis also
Figure 1. Mean level and number of measurements of FPG, HbA1c, 1-hour OGTT and 2-h OGTT during the 10-year follow-up.
doi:10.1371/journal.pone.0109506.g001
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supports this theory and is potentially due to baseline values being
poor surrogate markers for overall glycaemic control during
follow-up, thereby weakening the association with CVD, known in
epidemiology as regression dilution bias.
Debate continues over the type of glycaemic measure used to
screen for prediabetes. We have previously shown that monitoring
of HbA1c in prediabetic individuals is insensitive for the detection
of new cases of T2D [21,22]. Having the opportunity in this study
to analyse the importance of the current level of various glucose
measures, rather than using a baseline value several years old
which is often the case for baseline values, our results indicate that
the 2 hPG level is superior to other glucose measures including
HbA1c in predicting CVD. Hence, the current analysis supports
using OGTT as one tool in screening for prediabetes and to
monitor when treating patients with prediabetes. HbA1c is
probably also of predictive value for CVD when using the mean
level of repeated measurements and, therefore, of potential use
when following patients with existing prediabetes.
In the DECODE data there was no indication that a single
measure of FPG is of any use for the prediction of CVD risk at the
population level [6,11]. The only study in the population with
isolated IFG was negative [23]. Measurement of FPG for the
assessment of CVD risk has be discouraged by recommendations
provided in the current European guideline on Diabetes,
Prediabetes and Cardiovascular Disease [24]. In this study FPG
had no prognostic value of CVD when analyzing the whole
population in this study comprised by patients of IGT. However,
in a subgroup analysis of patients with IFG at baseline (76% of
included patients) there was an association between both baseline
and updated mean FPG with CVD. These results must however
be interpreted with caution since they were derived from a
subgroup analysis and the p-values were at the level 0.03–0.04.
Results from the Malmo¨ Feasibility Study, a non-randomised
study, and the Da Qing Study suggested that CVD rates might be
reduced in individuals with IGT who participated in lifestyle
intervention programmes [5,25]. The STOP-NIDDM trial,
including relatively few CVD cases, using acarbose as the
intervention in individuals with IGT showed a statistically
significant reduction in CVD rates [26]. Thus our results, that
post-challenge glucose was significantly associated with CVD risk
in DPS participants with IGT at baseline, are consistent with these
earlier findings. Unfortunately, none of these studies were designed
or powered to test the hypothesis of either therapy preventing
CVD in individuals with IGT. Also, our comparison using the
DPS cohort with the population-based cohort of Finnish people
with IGT and of the same age as the Malmo¨ Feasibility Study
showed that total mortality and CVD risk were markedly lower in
the DPS cohort irrespective of the intervention group [27].
Table 2. Hazard ratios of CVD for 1 unit increase in FPG, 1 hPG, 2 hPG and HbA1c.
Hazard Ratio (95% CI) P-value
Model 1 Model 2 Model 3 Model 4
Updated mean value
Mean Fasting Plasma Glucose (mmol/l) 1.67 (0.9223.03)
p = 0.09
1.53 (0.8222.85)
p = 0.18
1.60 (0.8523.00)
p = 0.14
1.66 (0.8923.12)
p = 0.11
Mean One-hour Plasma Glucose (mmol/l) 1.24 (1.0221.50)
p = 0.029
1.22 (1.0021.48)
p = 0.048
1.23 (1.0021.50)
p = 0.047
1.24 (1.0121.52)
p = 0.036
Mean Two-hour Plasma Glucose (mmol/l) 1.52 (1.1622.01)
p = 0.0027
1.48 (1.1121.97)
p = 0.0068
1.43 (1.0721.90)
p = 0.015
1.44 (1.0821.92)
p = 0.014
Mean HbA1c (%) 2.35 (1.2424.46)
p = 0.0088
2.23 (1.1724.27)
p = 0.015
2.29 (1.1924.42)
p = 0.013
2.73 (1.4025.32)
p = 0.0032
Updated value (last value prior to the CVD event)
Fasting Plasma Glucose (mmol/l) 1.35 (0.8222.20)
p = 0.24
1.25 (0.7622.08)
p = 0.38
1.27 (0.7622.11)
p = 0.37
1.31 (0.7822.19)
p = 0.31
One-hour Plasma Glucose (mmol/l) 1.20 (1.0321.40)
p = 0.020
1.18 (1.0121.38)
p = 0.033
1.18 (1.0121.39)
p = 0.039
1.19 (1.0221.40)
p = 0.03
Two-hour Plasma Glucose (mmol/l) 1.47 (1.2421.74)
p =,.0001
1.46 (1.2321.73)
p =,.0001
1.44 (1.2121.71)
p =,.0001
1.45 (1.2221.72)
p =,.0001
HbA1c (%) 1.82 (1.0523.16)
p = 0.033
1.75 (1.0123.06)
p = 0.048
1.79 (1.0223.15)
p = 0.044
1.98 (1.1123.51)
p = 0.020
Baseline value
Fasting Plasma Glucose (mmol/l) 1.53 (0.9322.51)
p = 0.097
1.42 (0.8422.41)
p = 0.19
1.53 (0.9022.58)
p = 0.11
1.61 (0.9522.72)
p = 0.077
One-hour Plasma Glucose (mmol/l) 1.18 (1.0021.38)
p = 0.0502
1.17 (0.9821.38)
p = 0.075
1.17 (0.9821.40)
p = 0.078
1.18 (0.9921.41)
p = 0.068
Two-hour Plasma Glucose (mmol/l) 1.25 (1.0021.55)
p = 0.052
1.20 (0.9621.52)
p = 0.11
1.16 (0.9221.47)
p = 0.21
1.16 (0.9221.47)
p = 0.22
HbA1c (%) 1.67 (0.9123.09)
p = 0.10
1.55 (0.8322.89)
p = 0.17
1.58 (0.8522.96)
p = 0.15
1.76 (0.9223.36)
p = 0.087
Model 1 Covariates: Age, Gender, Smoking.
Model 2 Covariates: Age, Gender, Smoking, BMI, Physical Activity.
Model 3 Covariates: Age, Gender, Smoking, BMI, Physical Activity, SBP, HDLC, LDLC.
Model 4 Covariates: Age, Gender, Smoking, BMI, Physical Activity, SBP, HDLC, LDLC, Previous CVD, Previous Cancer.
doi:10.1371/journal.pone.0109506.t002
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A limitation of the present study is the relatively small number
of patients and CVD events, (504 patients, 34 CVD events during
the prediabetic phase and a total of 52 events after the diagnosis of
diabetes). This implies that confidence intervals for the estimated
HRs are relatively wide. On the other hand, one major and
unique strength of this study is the repeated yearly recordings of
FPG, 1 hPG, 2 hPG and HbA1c over a long period of time,
information that is generally lacking in other studies due to many
logistical reasons. HbA1c has previously been associated with
CVD in people free of diabetes at baseline [28]. The current study
should not be regarded as disqualifying HbA1c as a screening tool
for diabetes, but rather showing additional benefits of 2 hPG over
and above HbA1c. Therefore 2 hPG has an essential role in
screening and monitoring prediabetic individuals. Similar meth-
odology as in previous studies of type 2 diabetes relating updated
mean HbA1c and baseline HbA1c to CVD events was used [29].
It should be noticed that evaluations of changes in risk by 1 SD
higher of the risk factor used here to compare the predictive power
of the various glucose measures may differ to some extent in other
populations if the HbA1c distribution differs relative to the glucose
measures’ distributions. However, it seems unlikely that the
glucose pattern at a certain Hba1c-level should be substantially
different in another population, especially if patients are not
treated with glucose-lowering drugs. Moreover, also the fact that
updated 2 hPG remained significant but updated HbA1c did not
in pairwise comparisons and 2 hPG generally showing lower p-
values in evaluated models supported its superiority as predictor.
In conclusion, this study demonstrates that level of glycaemic
control already existing in the prediabetic phase is strongly related
to risk of CVD. The current value of 2 hPG is the strongest
predictor for CVD and should be one tool in screening for
prediabetes and when monitoring the glycaemic control in patients
with prediabetes. Prospective studies are needed to test and
confirm these results from the DPS.
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